cerecin_logo_rgb.jpg
Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms
07 déc. 2022 06h00 HE | Cerecin
The authorization of the IND for Infantile Spasms (IS) is the third for tricaprilin, with other INDs open in Alzheimer’s disease and migraineA pilot study of CER-0001 in IS is ongoing in Australia and...
cerecin_logo_rgb.jpg
Cerecin Announces Abstract on New Infantile Spasms Data Accepted for Oral Presentation at the International League Against Epilepsy EME Congress 2022
03 nov. 2022 07h00 HE | Cerecin
SINGAPORE and DENVER, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced that a poster showcasing new...
cerecin_logo_rgb.jpg
Results of Pilot Study of CER-0001 in Migraine support advancement into a pivotal global Phase 2/3 study
31 oct. 2022 07h00 HE | Cerecin
Data from the RELIEF study, a pilot study assessing the safety and efficacy of the investigational compound CER-0001 in participants with migraine, showed a positive efficacy signal The outcome...
cerecin_logo_rgb.jpg
Cerecin appoints Dr. Marc Cantillon as Chief Medical Officer
10 oct. 2022 07h00 HE | Cerecin
Cerecin expands senior management team with appointment of Dr. Marc Cantillon as Chief Medical OfficerDr. Cantillon brings over 25 years experience in senior Central Nervous System (CNS) development...
cerecin_logo_rgb.jpg
Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development
28 sept. 2022 06h00 HE | Cerecin
Series IIB Financing was supported by existing and new investors in South Korea.Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile...
cerecin_logo_rgb.jpg
Cerecin Announces Appointment of Milan Vinnola as General Counsel
14 déc. 2021 07h00 HE | Cerecin
DENVER and SINGAPORE, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the appointment of...
cerecin_logo_rgb.jpg
Cerecin Enrolls First Patient in a Pilot Clinical Trial of Tricaprilin in the Treatment of Infantile Spasms
09 nov. 2021 07h00 HE | Cerecin
SINGAPORE and DENVER, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cerecin, a clinical-stage biotechnology company developing ketogenic agents as potential neurotherapeutics, today announced the enrollment of...
cerecin_logo_rgb.jpg
Cerecin raises $40 Million Series II and IIA financing to support its programs in neurological disorders
19 oct. 2021 07h00 HE | Cerecin
Prominent banks and institutional investors from South Korea follow an earlier cornerstone investment from Cerecin’s long-term partner, Nestlé.Proceeds will be used to fund product and pipeline...
cerecin_logo_rgb.jpg
Julie Liu Joins Cerecin From Pfizer as New Vice President of R&D and Chemicals, Manufacturing and Controls
04 févr. 2021 06h00 HE | Cerecin
Colorado USA, Melbourne Australia, and Singapore, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Cerecin, Inc. a clinical-stage biotechnology company pioneering ketogenic neurotherapeutics, today announced the...
cerecin_logo_rgb.jpg
Cerecin Enrolls First Patient in a Phase 2 Pilot Clinical Trial of Tricaprilin for Migraine Prevention (the Relief Study)
17 déc. 2020 07h40 HE | Cerecin
Colorado, USA and Melbourne, Australia, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on brain therapeutics, announced the enrollment of the first patient in its...